Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...

Pliant Therapeutics (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial ...

The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The company plans further data analysis.

The company is also progressing its other clinical assets, including PLN-101095 in oncology. The BEACON-IPF trial provided early evidence of efficacy for bexotegrast on the forced vital capacity ...

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...

Phase 1 trial of PLN-101095 in solid tumors continues to enroll, with interim data expected in the first quarter 2025. This is a Phase 1 open label trial of PLN-101095, an oral, small molecule ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a ...

Pliant is committed to the development of its other clinical and pipeline assets including PLN-101095 in oncology. The Company is currently enrolling the fourth of five planned dose cohorts in a ...